Ocrelizumab vs interferon beta‐1a
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
- RR 0.63 [0.57, 0.69]2 studies · 1656 participantsLow